MAP2K7 and lung carcinoma: In contrast, in lung cancer cells with a KRAS-mutation during the epithelial-to-mesenchymal transition, MEK inhibition activates the FGFR, so it has been reported that cotreatment of FGFR-TKIs and MEK inhibitors effectively inhibits cancer cell survival and tumor growth [44].